Acurx Pharmaceuticals to Present at the Emerging Growth Conference on July 12, 2023
- Investors can receive an update on Acurx Pharmaceuticals' current initiatives at the Emerging Growth Conference.
- None.
Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference.
Date: | Wednesday, July 12, 2023 |
Time: | 12:35 p.m. Eastern Time |
Your unique link to register is:
https://goto.webcasts.com/starthere.jsp?ei=1603282&tp_key=1cd1dcc46a&sti=axcp
This pre-recorded online event will provide current stockholders and the investment community the opportunity to receive an update on Acurx Pharmaceuticals and its current initiatives.
The presentation will be webcast at the aforementioned time, and archived for 30 days thereafter, via the Company's website at www.acurxpharma.com, under the Investors section.
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).
To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.
Forward-Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2022, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci
President & CEO
Tel: 917-533-1469
Email: davidluci@acurxpharma.com
View original content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-present-at-the-emerging-growth-conference-on-july-12-2023-301854520.html
SOURCE Acurx Pharmaceuticals, Inc.
FAQ
When is Acurx Pharmaceuticals presenting at the Emerging Growth Conference?
Where can I watch the presentation?
How long will the presentation be available for viewing?
